Table 3.

Intra-operative findings, distribution of cervical dilatation and complications by randomised treatment group

	Dosage group		P
	Self-administered vaginal placebo (n = 34)	Self-administered vaginal misoprostol (n = 33)
Cervical dilatation at hysteroscopy (mm), mean (SD)	4.7 (1.5)	5.7 (1.6)	0.01
Baseline cervical dilatation (mm) at inclusion, mean (SD)	2.1 (1.7)	2.6 (1.7)
Mean difference in cervical dilatation (mm) between inclusion and hysteroscopy (SD)	2.7 (1.7)	3.1 (1.9)
Number of patients achieving cervical dilatation ≥5 mm, n (%)	20 (59)	30 (88)
‘Difficult dilatation’, n (%)	7 (21)	1 (3)
Exposure to capsules (min), mean (SD)	726 (109)	750 (84)
Frequency of preoperative complications, n (%)	1 (3)	1 (3)
Complications within 14 days after hysteroscopy, n (%)	0	0